NCT02003573View on ClinicalTrials.gov

Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)

PHASE1TerminatedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

January 29, 2014

Primary Completion Date

January 6, 2015

Study Completion Date

May 15, 2016

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

decitabine iv

decitabine iv fixed dose

DRUG

volasertib iv infusion

volasertib iv infusion (Body Surface Area (BSA) based dosing)

Trial Locations (3)

63110

Washington School of Medicine, St Louis

77030

The University of Texas MD Anderson Cancer Center, Houston

06510

Yale Cancer Center, New Haven

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY